Top
Main
 
All Outcomes
 
Feedback
Home
c19early.org COVID-19 treatment researchBudesonideBudesonide (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

Loading...
More

Supplementary Data — Budesonide for COVID-19: real-time meta analysis of 15 studies

@CovidAnalysis, October 2024, Version 31V31
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ STOIC Ramakrish.. (RCT) 82% 0.18 [0.04-0.79] hosp./ER 2/73 11/73 Improvement, RR [CI] Treatment Control STOIC Ramakrish.. (RCT) 90% 0.10 [0.01-0.75] hosp./ER 1/70 10/69 STOIC Ramakrish.. (RCT) 67% 0.33 [0.15-0.72] no recov. 7/70 21/69 TOGETHER Reis (DB RCT) -200% 3.00 [0.12-73.5] death 1/738 0/738 CT​1 TOGETHER Reis (DB RCT) 12% 0.88 [0.32-2.40] hosp. 7/738 8/738 CT​1 TOGETHER Reis (DB RCT) 50% 0.50 [0.25-0.92] progression 13/738 27/738 CT​1 Ramlall (ICU) 71% 0.29 [0.11-0.78] death 33 (n) 915 (n) Intubated patients PRINCIPLE Yu (RCT) 39% 0.61 [0.22-1.67] death 6/787 10/799 PRINCIPLE Yu (RCT) 6% 0.94 [0.44-1.98] ventilation 13/776 14/784 PRINCIPLE Yu (RCT) 52% 0.48 [0.23-1.01] ICU 10/771 21/779 PRINCIPLE Yu (RCT) 25% 0.75 [0.55-1.03] death/hosp. 72/787 116/1,069 PRINCIPLE Yu (RCT) 17% 0.83 [0.74-0.93] recov. time 787 (n) 1,069 (n) Al Sulaiman (ICU) 32% 0.68 [0.41-1.13] death 30/64 31/64 ICU patients MP 80%​2 Al Sulaiman (ICU) 47% 0.53 [0.31-0.93] death 25/65 29/65 ICU patients MP 80%​2 Alsultan (RCT) -7% 1.07 [0.42-2.71] death 5/14 7/21 TACTIC Agustí (RCT) -23% 1.23 [0.08-19.0] death 1/40 1/49 TACTIC Agustí (RCT) 39% 0.61 [0.12-3.17] progression 2/40 4/49 Bhandari 67% 0.33 [0.01-8.02] death 0/60 1/60 Bhandari 33% 0.67 [0.49-0.90] oxygen time 60 (n) 60 (n) Bhandari 26% 0.74 [0.57-0.96] hosp. time 60 (n) 60 (n) Bhandari 37% 0.63 [0.48-0.84] recov. time 60 (n) 60 (n) Yang -11% 1.11 [0.62-1.97] death 30/125 13/60 Samajdar 58% 0.42 [0.08-2.05] death 2/50 5/52 CT​1 Samajdar 65% 0.35 [0.04-3.22] ventilation 1/50 3/52 CT​1 Samajdar 69% 0.31 [0.09-1.07] hosp. 3/50 10/52 CT​1 Samajdar 29% 0.71 [0.55-0.91] no recov. 50 (n) 52 (n) CT​1 Samajdar 10% 0.90 [0.80-1.02] no recov. 50 (n) 52 (n) CT​1 Dhanger (RCT) 43% 0.57 [0.18-1.80] death 4/40 7/40 Dhanger (RCT) 78% 0.22 [0.09-0.51] ICU 5/40 23/40 Dhanger (RCT) 70% 0.30 [0.16-0.55] no recov. 9/40 30/40 Lee 33% 0.67 [0.42-1.08] cases 19/1,674 95/5,345 Monserrat .. (PSM) 49% 0.51 [0.28-0.90] death n/a n/a Loucera 22% 0.78 [0.65-0.92] death 1,047 (n) 14,921 (n) Bai 31% 0.69 [0.40-1.19] hosp. 71 (n) 241 (n) CT​1 Bai 51% 0.49 [0.27-0.90] hosp. 10/71 69/241 CT​1 Bai 13% 0.87 [0.59-1.29] hosp. 30/129 49/183 CT​1 Bai 24% 0.76 [0.66-0.87] cases 71 (n) 241 (n) CT​1 Bai 17% 0.83 [0.69-0.99] cases 44/71 181/241 CT​1 Bai 29% 0.71 [0.61-0.83] cases 78/129 147/173 CT​1 Budesonide COVID-19 outcomes c19early.org October 2024 1 CT: study uses combined treatment2 MP: multiple medications, percentage budesonide shown Favors budesonide Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit